Frifelt 1996.

Methods	Study design: parallel RCT Study duration: NS Duration of follow‐up: NS
Participants	Country: Denmark Setting: single centre Hb < 9.7 g/dL; CAPD ≥ 3 months; age ≥ 18 years; rHuEPO started and adjusted before randomisation to reach target Hb 10.5 to 12.0 g/dL Number: treatment group 1 (16); treatment group 2 (17) Mean age ± SD (years): NS Sex (M/F): NS Exclusion criteria: immunosuppressive therapy; moderate or severe hypertension; anaemia due to other causes
Interventions	Treatment group 1 rHuEPO: SC once/wk for 3 months starting at 60 U/kg/wk Doses adjusted to maintain target Hb Treatment group 2 rHuEPO: SC 3 times/wk for 3 months starting at 60 U/kg/wk Doses adjusted to maintain target Hb Other information Type of EPO: recormon beta Co‐interventions IV and oral iron supplementation
Outcomes	Hb levels at end of study rHuEPO doses end of study
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"randomised, prospective study"
Allocation concealment (selection bias)	Unclear risk	Not mentioned
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Primary outcome was laboratory based and not likely to be influenced by blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcome was laboratory based and not likely to be influenced by blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	15% (6/39) excluded and missing data could have influenced final result; peritonitis (4); cerebral ischaemia (1); death due to AMI (1)
Selective reporting (reporting bias)	High risk	No reports on mortality and incomplete reporting of adverse effects. Results available only as median and IQR and cannot be entered in meta‐analyses
Other bias	High risk	Funded study by Ercopharm, Kvistgaard, Denmark